Sleep Expert Dr. Michael Breus Joins Health is a Skill Podcast with Todd Vande Hei to Share Tips for Long-Term Wellness
Beverly Hills California, June 19, 2025 (GLOBE NEWSWIRE) — Renowned clinical psychologist and sleep specialist Dr. Michael Breus joined Stark CEO Todd Vande Hei on the latest episode of Health is a Skill , delivering an insightful discussion on how simple daily habits—breathing, hydration, and sleep—can lead to profound long-term health improvements.
Dr. Breus, widely known as 'The Sleep Doctor,' is double board-certified and the author of multiple bestselling books, including The Power of When and his latest, Sleep, Drink, Breathe: Simple Daily Habits for Profound Long-Term Health . In this episode, he outlined his 'Three Fifteens' strategy—15 minutes of morning sunlight, 15 deep breaths, and 15 ounces of water—as a powerful wellness primer.
'These are things we're already doing—breathing, sleeping, drinking water. But doing them better can create exponential results,' said Dr. Breus. He emphasized that foundational habits often outperform more complex biohacks when implemented consistently and correctly.
The episode also breaks down the importance of chronotypes—genetically influenced sleep-wake tendencies—and how aligning daily activities to one's natural rhythm can optimize rest and performance. Dr. Breus introduced his ChronoQuiz tool as a way for listeners to understand their individual sleep types and tailor their daily routines accordingly.
Additional highlights from the discussion include: The connection between poor sleep and hydration, and how to spot dehydration through simple urine color checks. Breathwork techniques such as box breathing and the 4-7-8 method, useful for activating the parasympathetic nervous system. The critical impact of consistent wake-up times on melatonin regulation. Pros and cons of melatonin supplementation, and the limitations of common sleep tracking devices. The future of sleep diagnostics, including FDA-approved at-home tools like the Happy Ring.
Dr. Breus also shared insights on treating sleep disorders like insomnia and obstructive sleep apnea, covering treatment alternatives to CPAP machines such as dental appliances and new technologies like eXciteOSA. He stressed that while these devices are promising, foundational health behaviors remain the most impactful.
For those navigating sleep challenges or simply looking to improve their wellness baseline, Dr. Breus recommended starting with the fundamentals. 'If there's one thing people should do, it's wake up at the same time seven days a week,' he advised.
Listeners can hear the full conversation on YouTube, Spotify, or Apple Podcasts.
About Health Is a Skill
Health is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark. Through expert interviews and solo episodes, the podcast explores the systems, tools, and daily practices that optimize health and longevity in the modern world.
Media Communications:
Inquiries: [email protected]
Attachment Dr. Michael Breus, author of Sleep, Drink, Breathe, discusses sleep optimization with Todd Vande Hei.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
26 minutes ago
- Business Upturn
CLEAR Joins White House and CMS Effort to Power an Interoperable, Secure Digital Health Ecosystem
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — CLEAR (NYSE: YOU), the secure identity platform, is participating in the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem initiative, a nationwide effort to deliver a more connected, patient-centered healthcare system. CLEAR was proud to stand alongside government, healthcare, and technology leaders at the White House this week to support the launch of this national collaboration, and to reinforce its role as the trusted, full service Identity Assurance Level 2 (IAL2)/Authenticator Assurance Level 2 (AAL2) identity layer underpinning partner ecosystems across healthcare. 'CLEAR applauds the Administration's commitment to accelerating the digital transformation of healthcare and is proud to be a trusted partner in this nationwide effort,' said Caryn Seidman Becker, CEO of CLEAR. 'By serving as an IAL2 identity layer in healthcare ecosystems, CLEAR is helping to kill the clipboard, eliminate friction, and give patients control of their medical information in a secure, seamless way. We believe identity is the key to unlocking personalized, efficient, and patient-centered care.' At the heart of this CMS-led effort is a push to make health data more accessible, interoperable, and actionable, empowering patients, reducing provider burden, and improving outcomes. CLEAR's reusable identity platform for healthcare organizations and businesses, CLEAR1, is already enabling this transformation across leading platforms and health systems, including Epic, Surescripts, Wellstar, Community Health Network, University of Miami Health and These partners are leveraging CLEAR1 for use cases such as streamlining patient onboarding and check-in, enhancing workforce security, simplifying access to medical records, and strengthening data protection. Together, these efforts demonstrate how secure, interoperable identity can reduce friction, lower costs, and enable a more connected healthcare experience. CLEAR1 is a NIST IAL2/AAL2-compliant identity solution that gives patients and providers a reusable, privacy-centric credential to unlock services across the care journey, whether creating a MyChart account, verifying coverage, or accessing claims data. Over 60 companies have signed on to the CMS Health Tech Ecosystem pledge, committing to advance tools that: Help patients manage chronic conditions like diabetes and obesity Use AI assistants to navigate symptoms and schedule care 'Kill the clipboard' by digitizing check-in and intake Securely share data across trusted networks using modern identity credentials 'We are excited that identity services – like CLEAR – are making it possible for patients and providers to use verified, secure identity as part of CMS's Health Tech Ecosystem,' said Amy Gleason, Acting Administrator for the U.S. DOGE Service and Strategic Advisor to the Department of Health and Human Services and the Centers for Medicare and Medicaid. 'Checking in at the doctor's office should be the same as boarding a flight. Patients should be able to scan a QR code to instantly and safely share their identity, insurance and medical history'. 'Our work with CLEAR has meaningfully improved the speed and reliability of provider identity verification across our network,' said Frank Harvey, CEO of Surescripts. 'It's a powerful example of how focused collaboration can drive real progress. This pledge builds on that momentum—demonstrating how innovators across healthcare are advancing interoperability to reduce administrative burden and refocus clinicians' time where it matters most: patient care.' 'Identity is foundational to creating the connected, consumer-first healthcare experience that people expect, and it's what was built to deliver,' said Kristen Valdes, CEO and Founder of 'Our partnership with CLEAR brings a trusted, IAL2-compliant identity layer into that experience, giving patients and caregivers a seamless, unified way to access and share their health information across providers and platforms.' 'As part of our pledge to become a CMS Aligned Network, our relationship and planned integration with CLEAR will give us a unique opportunity to bring IAL2 identity verification to providers who are newer to the interoperability space,' said Therasa Bell, President and Founder of Kno2. 'That includes nurses, physical therapists, behavioral health providers, dentists, and paramedics, and it will enable them to securely communicate and share patient records across the broader healthcare ecosystem.' 'Modern identity is the key to enabling safe, secure, and trusted data exchange across healthcare,' said Aneesh Chopra, former Chief Technology Officer of the United States. 'CLEAR's work to deliver IAL2-compliant digital identity helps unlock the promise of interoperability—giving patients and providers the confidence to share information seamlessly and securely.' CLEAR1 is already powering many of these functions across CLEAR's health, financial services, and workforce partners—and stands ready to support the rollout of CMS-Aligned Networks in 2026 and beyond. About CLEAR CLEAR's mission is to strengthen security and create frictionless experiences. With over 31 million Members and a growing network of partners across the world, CLEAR's secure identity platform is transforming the way people live, work, and travel. Whether you are traveling, at the stadium, or on your phone, CLEAR connects you to the things that make you, you – making everyday experiences easier, more secure, and friction-free. CLEAR is committed to privacy done right. Members are always in control of their own information, and we never sell Member data. For more information, visit . Forward-Looking Statements This release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes, without limitation, statements relating to CLEAR's participation in the CMS Health Tech Ecosystem initiative. Investors are cautioned that any and such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors, including risks associated with the initiative and CLEAR's participation therein, and those described in the Company's filings within the Securities and Exchange Commission, including the sections titled 'Risk Factors' in our Annual Report on Form 10- K. The Company disclaims any obligation to update any forward-looking statements contained herein. CLEAR [email protected] This press release was published by a CLEAR® Verified individual. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
UPI
3 hours ago
- UPI
High Noon recalls vodka seltzer cans mislabeled as energy drinks
U.S. Food and Drug Administration High Noon is recalling some of its vodka seltzer packs after finding that a few cans were incorrectly labeled as non-alcoholic energy drinks. The U.S. Food and Drug Administration (FDA) said on Wednesday that two lots of the High Noon Beach Variety 12-pack contain cans labeled as "CELSIUS® ASTRO VIBE™ Energy Drink, Sparkling Blue Razz Edition." But the cans still contain alcohol, not energy drink liquid. "The recall was initiated after High Noon discovered that a shared packaging supplier mistakenly shipped empty CELSIUS cans to High Noon," the FDA said. The mislabeled cans can be identified by a silver top, rather than the usual black top on Celsius drinks. No one has gotten sick or reported health problems so far, but drinking alcohol by mistake could be dangerous - especially for people avoiding alcohol due to age, health or other reasons. The recalled seltzer 12-packs were sent to distributors in: Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin. Distributors shipped the product to retailers in Florida, New York, Ohio, South Carolina, Virginia and Wisconsin. The recalled High Noon Beach Variety 12-packs have this UPC code: 085000040065. Lot codes: L CCC 17JL25 14:00 to L CCC 17JL25 23:59 L CCC 18JL25 00:00 to L CCC 18JL25 03:00 The mislabeled Celsius cans have this UPC code: 8 89392 00134 1. Lot codes (found on the bottom of the can): L CCB 02JL25 2:55 to L CCB 02JL25 3:11 Customers who find they have one of the mislabeled cans should not drink it. Instead, they should throw it away and email consumerrelations@ to request a refund, the FDA said. More information Read the full recall notice at the U.S. Food and Drug Administration. SOURCE: U.S. Food and Drug Administration, July 30, 2025 Copyright © 2025 HealthDay. All rights reserved.
Yahoo
4 hours ago
- Yahoo
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis. In September 2021, Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as MONJUVI® in the United States and MINJUVI® outside of the U.S.), as well as PEMAZYRE® (pemigatinib), in Latin America. In February 2024, Knight announced the launch of MINJUVI® in Brazil in combination with lenalidomide followed by MINJUVI® monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). 'This regulatory submission for a new indication for tafasitamab in relapsed or refractory FL highlights our steadfast commitment to bringing innovation and enhancing quality of life and care,' said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics. 'If approved, the combination of tafasitamab, rituximab and lenalidomide will be an important new therapeutic option for eligible adult patients with previously treated FL in Brazil. We look forward to continuing to work towards regulatory submissions in additional countries in Latin America over the next months.' About Follicular Lymphoma (FL) and inMIND Study FL is the most common indolent, or slow growing, form of non-Hodgkin lymphoma (NHL).1 In Brazil, according to the 2023 data from the National Cancer Institute (INCA) Registries, the expected incidence/year of NHL (inclusive of all subtypes) was 5.57 per 100, 000 in the general population, 6.42 per 100,000 in the male population, and 5.62 per 100,000 in the female population. It is expected that follicular lymphoma constitutes 20% to 25% of adult NHL cases.2,3,4 There are limited treatment options for relapsed or refractory FL.5 The submission is based on the results from the pivotal Phase 3 inMIND trial, a double-blind, placebo-controlled trial randomizing 548 patients with relapsed or refractory FL to receive tafasitamab or placebo with lenalidomide and rituximab. Key results from the trial demonstrated that tafasitamab plus lenalidomide and rituximab significantly improved progression-free survival (PFS) in patients with relapsed or refractory FL compared to a placebo. The median PFS was 22.4 months in the treatment arm versus 13.9 months in the placebo arm, representing a 57% reduction in the risk of disease progression, relapse, or death. Secondary endpoints also showed improvements, with higher response rates and longer durations of response observed in the treatment arm.6 About MINJUVI® (tafasitamab)MINJUVI® (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. In the U.S., MONJUVI® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). MONJUVI® is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials. Additionally, MONJUVI® received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). In Europe, MINJUVI® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. XmAb® is a registered trademark of Xencor, Inc. MONJUVI, MINJUVI, the MINJUVI and MONJUVI logos and the 'triangle' design are registered trademarks of Incyte. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. References: Kaseb H, et al. Follicular Lymphoma. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Kanters S, et al. BMC Cancer. 2023;23:74. Smith SM, Salles G. Haematologica. 2022;107:4-6. Swerdlow SH, Campo E, Pileri SA, et al. Blood. 2016;127:2375-2390. Decision Resources Group. Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Landscape & Forecast. 2020. Sehn L H., et al. ASH Annual Meeting 2024; Late Breaking Abstract Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND). Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
